After more than a decade of discussions and several failed attempts to define a legal framework, Spain has finally joined the group of European countries that recognize medical cannabis within national legislation. In October 2025, the government approved Royal Decree 903/2025, officially opening the door for the use of standardized cannabis extracts for selected patients under a strictly controlled hospital-based regime.
At first glance, the Spanish model seems like a compromise, balancing the growing demand for medical cannabis with the need to maintain pharmaceutical discipline, supervision, and patient safety. On closer inspection, however, it becomes clear that Spain is taking a strategically designed step that treats cannabis not as a product, but as a medicinal substance.
What the Decree Actually Brings
The new legal framework stipulates that medical cannabis in Spain will be available only in the form of standardized extracts prepared exclusively in hospital pharmacies. These preparations can be dispensed only by specialist prescription and only after conventional therapy has failed.
The list of initial indications follows the European standard:
- chronic pain unresponsive to standard treatment,
- severe forms of epilepsy,
- spasticity associated with multiple sclerosis,
- nausea and vomiting caused by chemotherapy.
The decree allows this list to be expanded as new clinical evidence emerges, with guidance provided by AEMPS, the Spanish Agency for Medicines and Health Products. AEMPS will also play a central role by maintaining a registry of standardized preparations, defining monographs for active substances, and overseeing pharmacovigilance and quality control.
Flower Excluded, Extracts in the Spotlight
One of the most debated elements of the new legislation is the complete exclusion of dried cannabis flowers from the medical framework. Patients will not be able to legally obtain flower for vaporization or other forms of administration, a limitation that critics call unnecessary and counterproductive.
However, both the government and regulatory experts firmly defend this choice. Extracts, they argue, allow precise dosing, pharmaceutical standardization, and stability control. The goal is maximum pharmaceutical certainty, consistent concentration, defined THC and CBD content, and full batch traceability.
As a representative of AEMPS explained to El País:
“This is not a ban, it’s a guarantee. Patients must have absolute confidence that every milliliter of extract is identical, safe, and clinically validated.”
A “Prudent but Certain” Approach
The Spanish model deliberately mirrors the conservative European approach, similar to Germany’s early medical program in 2017, though with an even stronger emphasis on control and pharmacovigilance.
From a compliance and pharmaceutical quality perspective, the new framework is exceptionally rigorous. Every product must originate from approved GMP/GDP facilities, undergo chemical and microbiological validation, and fall under strict pharmacovigilance reporting. THC levels above 0.2% are explicitly defined as psychotropic substances, requiring full traceability, documentation, and periodic reporting in accordance with existing Spanish narcotics laws.
Expert and Patient Reactions
Reactions to the decree’s approval have been largely positive, though not without criticism.
Healthcare media and pharmaceutical companies call it a “historic step toward pharmaceutical legalization”, creating a “safe, predictable, and professionally guided framework.” Legal consultancies such as Osborne Clarke and DLA Piper highlight the clearly defined responsibilities and procedures, which will allow the emergence of a regulated segment of cannabinoid-based medicines, though under tight state supervision.
On the other side, patient associations and advocacy groups emphasize that restricting access to hospital settings only could lead to delays in treatment and unequal regional access. As one patient representative told Cannabis Health News:
“Legalization that stays behind hospital walls is a welcome beginning, but still unreachable for most patients.”
Market and Supply Chain Implications
From an industry perspective, Royal Decree 903/2025 represents a strategic business opportunity, especially for EU-GMP certified manufacturers of extracts and APIs. This decree officially opens the Spanish market for legal import and use of standardized cannabis raw materials, which hospital pharmacies will use for magistral preparation.
The model is closed and vertically managed. Suppliers will not deal with retail or wholesalers but will become part of the hospital supply chain. This implies:
- GDP compliance, including security and transport for psychotropic materials,
- direct interaction with AEMPS for registry and authorization procedures,
- and a heavy focus on stability studies, validated analytics, and documentation according to Ph. Eur. 3028.
As summarized by an analyst for the legal daily CincoDías:
“This market doesn’t open widely. It opens with quality. Those already aligned with AEMPS standards will hold a clear competitive edge.”
What Comes Next
In the coming months, AEMPS is expected to publish the first monographs and list of approved standardized extracts, which will form the foundation for hospital pharmacy preparations. Additional guidance on dosing, efficacy tracking, and adverse event reporting will follow.
Together, these steps will enable a gradual expansion of the medical cannabis program, potentially to more indications or dosage forms, once sufficient clinical and pharmacovigilance data are collected. In other words, Spain is betting on evolution, not revolution.
Royal Decree 903/2025 marks a strategic, legally and technically balanced milestone. It introduces medical cannabis under full pharmaceutical supervision, emphasizing safety, standardization, and traceability.
For patients, the approach may feel overly restrictive. For regulators and healthcare professionals, it is a structured, evidence-based foundation for future development within a strictly controlled framework.
From an industry standpoint, it sends a clear signal. The era of extracts has begun. Companies with a GMP-certified portfolio, validated stability data, and transparent GDP logistics now have a genuine opportunity to enter one of Europe’s newest regulated markets, legally, transparently, and with pharmaceutical credibility.
Spain has finally entered the era of medical cannabis, not with fanfare, but with precision. At a time when parts of Europe are experimenting with recreational liberalization, Madrid has chosen the path of disciplined pharmaceutical integration. And that may prove to be exactly what ensures long-term sustainability, trust, and quality in this emerging field.
Source: https://www.linkedin.com/pulse/spain-legalizes-medical-cannabis-jakub-horak-imvec/
